DIASORIN RECEIVES FDA CLEARANCE IN THE US FOR ITS NEWLY DEVELOPED LIAISON® 25 OH VITAMIN D TOTAL ASSAY

February 2, 2012 - Saluggia (VC) - DiaSorin S.p.A. (FTSE MIB:DIA) announces today that the company has received FDA clearance of its newly developed LIAISON® 25 OH Vitamin D TOTAL Assay for the quantitative determination of 25 OH Vitamin D on its proprietary LIAISON® platform.

DiaSorin is the worldwide leader in Vitamin D testing. Today it has over 50% of the Vitamin D testing performed globally. As a market leader, in the last 10 years it has dedicated a significant effort to the research and development of products for Vitamin D testing. In the US, DiaSorin introduced its first fully automated assay for determination of 25 OH Vitamin D on the LIAISON® platform in 2004 and subsequently launched a second generation assay in 2007. Since initial product release, DiaSorin has sold over 130 million LIAISON® 25 OH Vitamin D tests worldwide.

To maintain its leadership position in this field, over the last two years DiaSorin’s scientists have developed this new product intended to be used on the LIAISON instrument and designed to improve certain features of the previous product, establishing a new standard in Vitamin D testing.

Dr. Carlo Rosa, CEO of DiaSorin Group, commented “I am really proud of this achievement. It shows our commitment to the field of Vitamin D testing where, as leaders, we need to be innovators. Among all companies that try to play a role in this space, as leaders we have the responsibility to continuously improve the quality of our products. We need to make testing easier for our customers, especially in those cases like Vitamin D where the surge of medical interest has created a rapid growth of testing volume putting laboratories under pressure to deliver quality results with a rapid turnaround time.”

For further information regarding this announcement please contact:

Riccardo Fava
External Relations Director - Head of IR and Media
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Laura Villa
Investor Relations Director
Tel: +39.02.96474567
laura.villa@diasorin.it